| Application no. and date | 22728724.0 (espacenet) (Federated) (European Patent Register), 20220516 | | Patent/reg. no. and date | DK/EP 4185318, 20250903 | | Publication date | 20230531 | | Priority no. and date | US 202163189541 P, 20210517, US 202163235398 P, 20210820, US 202263297420 P, 20220107, US 202263306315 P, 20220203 | | EP pub. no. and date |
EP 4185318 20230531 | | Effective date | | | Applicant/owner | Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road
Tarrytown, NY 10591, US,
Bayer HealthCare LLC, 100 Bayer Boulevard
Whippany, NJ 07981, US | | Applicant ref. no. | V496041DK00 | | Inventor | VITTI, Robert L.,
Tarrytown, New York 10591, US,
BERLINER, Alyson J.,
Tarrytown, New York 10591, US,
CHU, Karen,
Tarrytown, New York 10591, US,
ASMUS, Friedrich,
14129 Berlin, DE,
DA SILVA LEAL, Sergio Casimiro,
4153 Reinach, CH,
EISSING, Thomas,
40764 Langenfeld, DE,
RITTENHOUSE, Kay D.,
Randolph, NJ 07869, US | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 38/17 (2006.01) , A61P 27/02 (2006.01) | | Title | Forlængede, højdosis-VEGF-antagonistregimer til behandling af angiogene øjensygdomme | | Int. application no. | US2022029462 | | Int. publication no. | WO2022245739 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
